BPC-157 and TB-500: dosing in the published literature

BPC-157: no validated dosing regimen exists

BPC-157 is a synthetic pentadecapeptide, one of the repair peptides, first described by Sikiric and colleagues in 1993. Reviews of its development status are direct about where it stands: despite three decades of preclinical work there is no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial.

Human exposure has been limited to safety trials. The compound entered clinical development for inflammatory bowel disease under the code PL14736 (Pliva, Croatia) and was reported safe in that setting, but a safety trial establishes tolerability, not an effective dose for any other purpose.

A further limitation is rarely stated on commercial pages. Analyses of the literature attribute more than eighty per cent of published BPC-157 studies by author affiliation to a single research group at the University of Zagreb. Independent replication across separate laboratories is the normal precondition for treating preclinical findings as robust, and here it is largely absent.

Where the circulating BPC-157 numbers come from

The microgram-per-kilogram figures that appear in online dosing charts originate in rodent studies. Animal dosing does not transfer to humans by direct arithmetic — allometric scaling, route of administration, formulation and bioavailability all intervene, and none of those steps has been validated for this compound.

A dosing chart presented without that context is not reporting evidence. It is presenting an extrapolation as though it were a finding.

TB-500 and thymosin beta-4: real human trials, different application

Thymosin beta-4 has genuinely been through human clinical trials, which distinguishes it from BPC-157. Those trials were run by RegeneRx and are registered publicly: a Phase II study of thymosin beta-4 ophthalmic solution in dry eye (NCT01387347), and a double-blind placebo-controlled dose-response study in venous stasis ulcers (NCT00832091). A Phase III trial of RGN-259 in neurotrophic keratopathy has also been published.

The application matters. Those trials studied topical and ophthalmic administration for eye-surface and wound-healing indications. They are not trials of systemic injection for tendon, ligament or muscle repair, which is the use most readers are researching. The human safety data comes from a route and an indication that do not match.

There is also a naming issue. TB-500 as sold is commonly a fragment rather than full-length thymosin beta-4, so trial data on the full-length protein does not automatically describe the material in circulation.

What Body Pharm states about its own pen

Body Pharm supplies BPC-157 and TB-500 together in one pre-loaded 32 mg 3 mL pen (see what BPC-157 and TB-500 are), lists it under peptides for recovery, and describes its own protocol on the product page: commonly 250–500 mcg of each compound daily across a four- to eight-week window, with consistency of timing emphasised over dose size. That is the supplier’s stated protocol, not a result from any trial cited above.

Every batch is third-party tested for identity, purity and sterility, with the certificate of analysis for the specific lot reachable from the QR code on the pen.